Abstract: The invention relates to a method for generating ultrasonic waves focused on a focal zone (5) in order to carry out biological lesions, comprising the activation of a plurality of ultrasonic transducer elements (3). According to the invention: a target zone, in which homogenization of the supply of energy of the ultrasonic waves emitted by the ultrasonic transducer elements is desired, is chosen, the focusing effect and the acoustic attenuations of the ultrasonic waves on their path between the target zone and the ultrasonic transducer elements (3) are determined, the focusing effect and the acoustic attenuations of the ultrasonic waves are compensated, with ultrasonic transducer elements (3) at least some of which have non-identical emission surfaces such that in the target zone, the supply of energy of the ultrasonic waves emitted by the different ultrasonic transducer elements (3) is more or less identical.

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of age-related macular degeneration (AMD). In particular the present invention relates to RdCVFL polypeptide or polynucleotide for use in the treatment of AMD.

Abstract: Antagonist of the BTLA/HVEM interaction for use in therapy The present invention relates to an antagonist of the BTLA/HVEM interaction for use in therapy, wherein said antagonist increases the proliferation of V?9V?2 T cells.

Abstract: The method determines parameters to generate confocal ultrasound beams (B1,B2) inside a medium (4), and uses a device (1) comprising first and second ultrasound means (11,12) and first and second displacement members (13,14) for moving the ultrasound means (11,12). The parameters include signals s1,s2 to the ultrasound means (11,12), and the positions x1,x2 of the ultrasound means (11,12). The parameters are optimized for having a minimum amplitude a1,a2 of the signals s1,s2 and having an acoustic effect inside the medium (4).

Abstract: The present invention relates to an in vitro use of a number of IL-4 and/or IL-13 secreting T-cells as a biomarker for diagnosing and/or monitoring an IgE-dependent allergic disease.

Abstract: A method for discriminating carbapenem-resistant bacteria according to whether or not they develop resistance by membrane impermeability, the method including the following steps: providing a bacterial strain that is resistant to at least one carbapenem, evaluating the sensitivity of the bacterial strain with regard to at least one indicator carbapenem, on the one hand in the absence of polymyxin B nonapeptide (PMBN) and, on the other hand, in the presence of PMBN in a non-inhibitory concentration, establishing a prognosis of resistance by membrane impermeability in the case where the presence of PMBN makes it possible to significantly increase the sensitivity of the bacterial strain with regard to at least one indicator carbapenem used.

Abstract: The present invention relates to pharmaceutical and food compositions for inducing satiation and prolonging satiety in subjects in need thereof. In particular, the present invention relates to a method of inducing satiation in a subject in need thereof comprising administering to the subject an effective amount of a ClpB protein or an effective amount of a bacterium that expresses the ClpB protein.

Abstract: The present Inventors demonstrated that the RelB subunit of NF?B plays a crucial role in promoting cell migration. More precisely, they identified that this pro-migratory activity is mediated by the activation of the NF?B pathway through RelB phosphorylation at serine 472. In a first aspect, the present invention proposes to monitor the activation of the NF?B pathway by following the phosphorylation status of said serine. Also, the present invention discloses methods and kits for prognosing the evolution of a disease involving cell migration in a subject—treated or not—suffering thereof, based on the detection of said RelB-S472 phosphorylation.

Abstract: The present invention relates to transgenic mice and isolated transgenic mouse cells, the mice and mouse cells comprising a disrupted H2 class I gene, a disrupted H2 class II gene, a functional HLA class I transgene, and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cells are deficient for both H2 class I and class II molecules, wherein the transgenic mouse comprises a functional HLA class I transgene and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cell has the genotype HLA-A2+HLA-DR1+?2m°IA?°. The invention also relates to methods of using a transgenic mouse of the invention.

Abstract: The present invention relates to methods and pharmaceutical compositions for cardioprotection of subjects who experienced a myocardial infarction. In particular, the present invention relates to a ligand of the sonic hedgehog signaling pathway for use in the cardioprotection of a subject who experienced a myocardial infarction.

Abstract: The invention features soluble FGF decoy polypeptides and fusion polypeptides comprising an FGF decoy polypeptide linked to a heterologous polypeptide, such as an aggrecan binding protein. Both soluble FGF decoy polypeptides and fusion polypeptides can be used to prevent or treat skeletal disorders, such as achondroplasia.

Abstract: The present invention relates to a method and compositions for the treatment of cystic fibrosis.

Abstract: The invention relates to the treatment of neurodegenerative diseases, in particular Alzheimer's disease, by inhibition of the synthesis of ?APP or of the activity of the A? peptide in the choroid plexus.

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of bacterial infections in patients suffering from cirrhosis. In particular, the present invention relates to a method of treating bacterial infection in a patient suffering from cirrhosis comprising administering to the patient a therapeutically effective amount of a TLR7 and/or TLR8 agonist.

Abstract: The present invention stems from the finding that the extracellular domain of CD31 proteins present on blood leukocytes is shed and released in the circulation as a soluble form of CD31. A method for detecting shed CD31 is further disclosed. The invention therefore relates to a method for detecting a shed ectodomain of a transmembrane protein such as CD31 and to the use of such a method as a diagnostic tool. The invention further provides methods for determining whether a candidate protein is part of a molecular complex.

Abstract: A composition for treating Neurodegenerative Diseases with Parkinsonian Syndromes in a subject in need thereof, wherein the composition includes an effective amount of a modulator of a chloride transporter.

Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4+ T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.

Abstract: The invention relates to a module (6) for producing an MRI and/or MRS reference signal (S0), characterized in that the module comprises: a first receiving input (621) for receiving of an MRI and/or MRS synchronization signal (S3), a second receiving input (612) for receiving of a time signal (S8) of external stimulation, supply means (62) for supplying of a prescribed signal (RV) representing an MRI and/or MRS virtual object (RVV), generating means for generating of the MRI and/or MRS reference signal (S0), for temporally varying the MRI and/or MRS reference signal (S0) in the same way as a time characteristic determined from the time signal (S8) of external stimulation and in synchronization with the MRI and/or MRS synchronization signal (S3), a supply output (632) for supplying of the MRI and/or MRS reference signal (S0).

Abstract: The present disclosure relates to methods and pharmaceutical compositions for the treatment of hepatocellular carcinomas (HCC in abbreviation, the term “hepatocellular carcinoma” has its general meaning in the art and refers to the cancer developed in hepatocytes see page 2 lines 24-30 of the present application) comprising administering to the subject a therapeutically effective amount of an inhibitor of NTSR1 (Neurotensin Receptor 1) activation or expression. The examples show the expression of NTSR1 in HCC cell lines and the role of the NTS/NTSR1 complex in these cell lines, thereby showing the role of the complex in tumour progression.

Abstract: The present invention relates to the use of an hydrogel comprising silylated biomolecule for the three-dimensional culture of cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and to an aqueous composition comprising i) cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and ii) a hydrogel comprising silylated biomolecule, for use for treating heart failure, in particular heart failure following myocardial infarction.